SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

01 Feb 2023 Evaluate
The company witnessed a 8.20% growth in the revenue at Rs. 8748.90 millions for the quarter ended December 2022 as compared to Rs. 8085.80 millions during the year-ago period.Profit after Tax for the quarter ended December 2022 saw a decline of -36.34% from Rs. 1947.10 millions to Rs. 1239.60  millions.Operating profit for the quarter ended December 2022 decreased to 1899.20 millions as compared to 2657.70 millions of corresponding quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 8748.90 8085.80 8.20 25624.10 23750.10 7.89 31406.40 27185.90 15.52
Other Income 305.10 279.00 9.35 1443.00 1113.10 29.64 1397.30 1035.70 34.91
PBIDT 1899.20 2657.70 -28.54 6507.50 8150.50 -20.16 10306.20 10204.80 0.99
Interest 26.80 7.00 282.86 40.20 19.40 107.22 91.20 69.00 32.17
PBDT 1872.40 2650.70 -29.36 6467.30 8131.10 -20.46 10215.00 10135.80 0.78
Depreciation 322.90 307.10 5.14 948.40 908.70 4.37 1209.60 1114.90 8.49
PBT 1549.50 2343.60 -33.88 5518.90 7222.40 -23.59 9005.40 9020.90 -0.17
TAX 309.90 396.50 -21.84 1103.80 1372.20 -19.56 1806.80 2264.50 -20.21
Deferred Tax 134.60 66.60 102.10 55.20 130.00 -57.54 95.10 97.70 -2.66
PAT 1239.60 1947.10 -36.34 4415.10 5850.20 -24.53 7198.60 6756.40 6.54
Equity 257.10 173.90 47.84 257.10 173.90 47.84 171.70 173.90 -1.27
PBIDTM(%) 21.71 32.87 -33.96 25.40 34.32 -26.00 32.82 37.54 -12.58

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×